A pilot study presented at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference highlights the potential of a finger-prick blood test to measure p-tau217, a key biomarker for Alzheimer’s disease (AD). The study demonstrated a strong correlation between p-tau217 levels from capillary dried plasma spot (DPS) samples and standard venous plasma. Capillary samples, collected…
Category: Dementia
EMA reverses decision on Leqembi (lecanemab)
14 November 2024: The EMA has today partially approved a marketing application for Leqembi (Biogen/Eisai), having previously rejected it it July 2024, saying that the side effects outweighed the benefits. “After re-examining its initial opinion, the EMA… has recommended granting marketing authorisation to Leqembi (lecanemab) for treating mild cognitive impairment or mild dementia due to…
MHRA approves donanemab…
…but NICE says it does not demonstrate value for the NHS The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for donanemab, an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer’s disease in eligible adults in Great Britain. Eligible patients are limited to…
Bepranemab Phase 2a study
Results accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting 22nd October 2024: UCB today announced that the results of its double-blind TOGETHER (AH0003) Phase 2a study of bepranemab – an investigational anti-tau antibody – in people living with prodromal to mild Alzheimer’s Disease (AD), have been accepted for presentation in…
Cannabis-based medicine for neurodegenerative diseases
Avextra announces the approval of NEUROBIS by the Italian Medicines Agency: A Phase II clinical trial Avextra AG, a European manufacturer and developer of Cannabis-based medicines located in Germany, has announced that both the Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for a multi-centre Phase II study to…
Rewriting the story of dementia
Poetry book challenges mainstream media portrayal In the palm of a spider’s hand by Gerald King, who was diagnosed with young-onset Alzheimer’s at 55, aims to challenge the dehumanising narratives about dementia perpetuated by mainstream media. This publication seeks to redefine how we understand and engage with the lived dementia experience. King’s words liken Alzheimer’s…
Leqembi® (lecanemab) authorised for early Alzheimer’s disease in Great Britain
In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)* heterozygotes or non-carriers1 Great Britain becomes the first country in Europe to authorise the medicine, which targets an underlying cause of AD1 Authorisation based…
Valiltramiprosate -oral Aβ-targeting therapy for Alzheimer’s disease
American clinical-stage biopharmaceutical company Alzheon has recently presented promising interim results from its Phase II Biomarker Trial (NCT04693520) of its oral, brain-penetrant, amyloid-oligomer inhibitor ALZ-801 (valiltramiprosate) at the American Academy of Neurology 2024 annual meeting. ALZ-801 has the potential to be the first oral Aβ-targeting therapy to be approved in the US and EU in…
Alzheimer’s drug lecanemab rejected by EMA
On 25 July 2024 the European Medicines Agency (EMA) rejected a licence for lecanemab to treat Alzheimer’s disease. The EMA said the benefits did not counterbalance the risk of serious side effects, especially bleeding and swelling in the brain. The MHRA in the UK is still considering whether to grant a licence, and a decision is…
